Literature DB >> 1810100

Early detection of ovarian cancer: background, rationale, and structure of the Yale Early Detection Program.

P E Schwartz1, J T Chambers, K J Taylor, J Pellerito, L Hammers, L A Cole, T L Yang-Feng, P Smith, S T Mayne, R Makuch.   

Abstract

Ovarian cancer has received national attention as a highly virulent disease. Its lack of early warning symptoms and the failure to develop highly sensitive screening tests have led some physicians to recommend prophylactic oophorectomies to women with relatives who have had ovarian cancer. Others have recommended routine screening of otherwise normal women for CA 125, a circulating tumor marker, and ultrasound examinations. Each of these techniques is associated with substantial false-positive rates that could lead to unnecessary surgery. A review of epidemiologic data suggests that familial ovarian cancer kindreds are rare, but women with first-degree relatives who have had ovarian cancer have a significant risk themselves for developing ovarian cancer. In addition, women with a great number of ovulatory cycles are at an increased risk for the disease. Circulating tumor markers are frequently elevated in women with advanced ovarian cancer, but their value in early detection of ovarian cancer has yet to be established. Advances in endovaginal ultrasound and color Doppler flow technology have significantly improved our ability to assess pelvic organs. This article presents the background, rationale, and structure of the Yale Early Detection Program for ovarian cancer, whose goals are to identify the best techniques for diagnosing ovarian cancer in an early stage, to determine the frequency with which such tests should be employed, to assess false-positive results, and to identify women who might benefit from prophylactic oophorectomies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810100      PMCID: PMC2589429     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  54 in total

1.  Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity.

Authors:  J H Nam; L A Cole; J T Chambers; P E Schwartz
Journal:  Gynecol Oncol       Date:  1990-03       Impact factor: 5.482

2.  Familial Ovarian Cancer Registry.

Authors:  M S Piver; C J Mettlin; Y Tsukada; P Nasca; P Greenwald; M E McPhee
Journal:  Obstet Gynecol       Date:  1984-08       Impact factor: 7.661

3.  Factors affecting the association of oral contraceptives and ovarian cancer.

Authors:  D W Cramer; G B Hutchison; W R Welch; R E Scully; R C Knapp
Journal:  N Engl J Med       Date:  1982-10-21       Impact factor: 91.245

4.  Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families.

Authors:  J K Tobacman; M H Greene; M A Tucker; J Costa; R Kase; J F Fraumeni
Journal:  Lancet       Date:  1982-10-09       Impact factor: 79.321

5.  Determinants of ovarian cancer risk. I. Reproductive experiences and family history.

Authors:  D W Cramer; G B Hutchison; W R Welch; R E Scully; K J Ryan
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

6.  Dietary animal fat in relation to ovarian cancer risk.

Authors:  D W Cramer; W R Welch; G B Hutchison; W Willett; R E Scully
Journal:  Obstet Gynecol       Date:  1984-06       Impact factor: 7.661

7.  Epithelial carcinoma of the ovary: current strategies.

Authors:  M E Katz; P E Schwartz; D S Kapp; S Luikart
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

8.  Preoperative serum tumor-associated antigen levels in women with pelvic masses.

Authors:  J T Soper; V J Hunter; L Daly; M Tanner; W T Creasman; R C Bast
Journal:  Obstet Gynecol       Date:  1990-02       Impact factor: 7.661

9.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

10.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.